References
- Wildiers H, Reiser M. Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol 2011;77:221–240.
- Pfreundschuh M, Schubert J, Ziepert M, . Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–116.
- Watanabe T, Tobinai K, Shibata T, . Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent B-cell non-Hodgkin's lymphoma: JCOG 0203 Trial. J Clin Oncol 2011;29: 3990–3998.
- Aapro MS, Bohlius J, Cameron DA, . 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011;47:8–32.
- Barron R, Michels SL, Reynolds MW, . Risk of mortality in patients with cancer experiencing febrile neutropenia. J Clin Oncol 2009;27(Suppl.): Abstract 9561.
- Haioun C, Salar A, Pettengell R, . Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an obser-vational study. Leuk Lymphoma 2011;52:796–803.
- Aapro MS, Cameron DA, Pettengell R, . EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433–2453.
- Bosly A, Bron D, Hoof A, . Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 2008;87:277–283.
- Lyman GH, Kuderer NM, Crawford J, . Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2010;117:1917–1927.
- Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist 2005;10:427–437.
- Lyman GH, Dale DC, Friedberg J, . Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004;22: 4302–4311.
- Pettengell R, Schwenkglenks M, Leonard R, . Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 2008;16:1299–1309.